Physician profile
Adrienne Smith
NPI 1245948132
$4,510.45
in general payments reported to CMS, 2019-2025
23 companies · $721 in 2025
The $721 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,010 · 2024: $2,780 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,510.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $908.77 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $834.31 | 2023-2025 | |
| Novo Nordisk INC | $545.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $488.53 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.77 | 2023-2025 | Jardiance, Ofev, Spiriva Respimat |
| Lilly USA, LLC | $237.44 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $207.32 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $165.57 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $164.25 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $157.88 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $106.09 | 2024-2025 | |
| Esperion Therapeutics, INC. | $52.00 | 2023-2024 | Nexletol |
| Amgen INC. | $48.69 | 2023-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $47.92 | 2023-2025 | Verquvo, Capvaxive |
| Exact Sciences Corporation | $44.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $38.34 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.50 | 2023-2024 | Xifaxan, Trulance |
| Neurocrine Biosciences, INC. | $26.99 | 2025 | |
| Abbott Laboratories | $21.80 | 2025 | Freestyle Libre 3 |
| Sumitomo Pharma America, INC. | $20.52 | 2024 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $20.01 | 2024 | Voquezna |
| Valinor Pharma, LLC | $18.83 | 2024 | Movantik |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.88 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.